Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rocket Pharmaceuticals, Inc. - Common Stock (NQ: RCKT ) 11.77 -0.25 (-2.08%) Streaming Delayed Price Updated: 2:24 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 595,551 Open 11.97 Bid (Size) 11.76 (7) Ask (Size) 11.79 (6) Prev. Close 12.02 Today's Range 11.60 - 12.32 52wk Range 11.15 - 32.52 Shares Outstanding 65,837,894 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock December 11, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock December 10, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Performance YTD -60.10% -60.10% 1 Month -16.58% -16.58% 3 Month -33.13% -33.13% 6 Month -45.08% -45.08% 1 Year -63.15% -63.15% More News Read More 3 Small-Cap Stocks That Are Ready to Rocket Higher November 27, 2024 Via MarketBeat Topics Government Exposures Political Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference November 26, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst November 19, 2024 Via Benzinga Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference November 18, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions November 12, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference November 08, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress November 07, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease September 17, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors September 10, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences August 27, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday August 26, 2024 Via Benzinga RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 August 05, 2024 Via InvestorPlace Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress August 05, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides June 28, 2024 Via Benzinga Exposures Product Safety Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session June 28, 2024 Via Benzinga Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) June 28, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains June 14, 2024 Via Talk Markets Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy May 29, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 10, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 May 06, 2024 Via InvestorPlace Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress May 06, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia April 02, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team March 26, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
